Atlanta, Georgia (January 11, 2021) – Georgia Bio, the state’s public policy and business solutions organization representing Georgia’s life sciences sector, announced today that President and CEO Maria Thacker-Goethe was named to Georgia Trend magazine’s “100 Most Influential Georgians” list for 2021.

“It is an incredible honor to be chosen amongst such esteemed colleagues,” said Maria Thacker-Goethe, Georgia Bio’s president and CEO. “The list contains several of our life sciences partners, exhibiting the influence and impact that our sector has on the state of Georgia. Thank you to Georgia Trend for the merit and for highlighting the importance of the life sciences to our state.”

In its 23 rd year, this year’s “100 Most Influential Georgians” list contains CEOs, politicians, college presidents, nonprofit and economic development leaders who “have risen to the challenges of the past year to help make life better for all Georgians.”

Per Georgia Trend : “Under Thacker-Goethe’s leadership, Georgia Bio cultivates a high-growth life sciences

sector vital by many measures, including the nearly 200,000 jobs and approximately $22-billion impact for Georgia. She not only brings 13-plus years of nonprofit management to the role, but also the vision and experience from her concurrent leadership roles at the Georgia BioEd Institute and Global Health Alliance.”

To read more and view the full list of recipients, click HERE.

Thacker-Goethe also serves as CEO for the Center for Global Health Innovation. Georgia Bio is a division of The Center for Global Health Innovation, an Atlanta based 501(c)3 organization that was launched in 2020 to bring together diverse Global Health, Health Technology and Life Sciences entities to collaborate, innovate and activate solutions to enhance human health outcomes around the world. ( innovateglobalhealth.org )

About Georgia Bio

Georgia Bio ( www.gabio.org ) is the state’s private, non-profit life sciences association. Members include pharmaceutical, biotechnology and medical device companies, medical centers, universities and research institutes, government groups and other business organizations involved in the development of life sciences related products and services.

Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

By Sheran Brown • February 21, 2025
Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

Bipartisan PBM Reform Back in Focus as House Committee Plans Hearing

By Sheran Brown • February 20, 2025
A renewed push for prescription drug cost reform is gaining momentum in Congress, with the House Energy and Commerce Committee's health subcommittee planning a hearing on pharmacy benefit manager (PBM) reform for late February. The hearing, to be led by Rep. Buddy Carter (R-Ga.), signals a revival of bipartisan efforts to regulate these pharmaceutical intermediaries. PBMs, which negotiate drug prices for insurers and employers, have become a focal point in the broader discussion of healthcare costs. A previous bipartisan agreement to regulate these entities was crafted by Carter and Rep. Diana DeGette (D-Colo.) in the last Congress, though it ultimately stalled when the larger spending bill it was attached to faced opposition. The reform efforts enjoy broad support from both parties and the president, making it one of the few areas with potential for bipartisan cooperation. However, new complications have emerged as Republicans consider using PBM regulations to generate savings for their broader policy agenda, potentially requiring up to $880 billion in cost reductions. The path forward remains uncertain, with ongoing debates about whether such reforms would qualify for budget reconciliation and whether using PBM regulations as a funding mechanism could derail bipartisan cooperation. Meanwhile, stakeholders continue to disagree on the impact of additional PBM regulation, with pharmaceutical companies arguing that PBMs inflate drug costs while PBMs contend that new regulations would increase prices.

Council on State Biotechnology Associations says NIH funds are a critical component of innovation ecosystem

By Sheran Brown • February 20, 2025
The Council of State Biotechnology Associations (CSBA) has issued a strong warning about proposed cuts to National Institutes of Health (NIH) funding, emphasizing the critical role these grants play in America's biotech innovation ecosystem. The statement, below , comes amid concerns over recent guidance that would reduce NIH funding to key research institutions. ----------------------- “Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a successful drug, the private sector invests over $65, underscoring the agency’s unparalleled return on investment. As the associations representing the bioscience industry across the nation, the Council on State Biotechnology Associations (CSBA) is concerned by recent guidance that would cut funding provided by the NIH to universities, hospitals, and other institutions that perform critical early-stage research. NIH grant funds are a critical component of our innovation ecosystem. Grants for basic research are the spark that leads to university-driven discoveries, with public-private partnerships and tech transfers that bridge early-stage research to industry-sponsored drug development and ultimately to FDA approved medical advances for hundreds of diseases. While the administration looks for greater efficiency in the use of taxpayer dollars, it cannot be overstated - once scientific innovation moves abroad, it may never return. In the race for scientific innovation around the world, as our adversaries continue to increase government investments in research, we encourage President Trump to follow suit and ensure that we maintain our global leadership in an industry that was created and thrives across the US.”
MORE POSTS
Share by: